IL-1 binding proteins

• US 9,441,038 B2
• Filed: 12/17/2013
• Issued: 09/13/2016
• Est. Priority Date: 05/14/2010
• Status: Active Grant

• Current Assignee: Abbvie Incorporated
• Original Assignee: Abbvie Incorporated
• Inventors: Wu, Chengbin, Ambrosi, Dominic J., Hsieh, Chung-ming, Ghayur, Tariq
• Primary Examiner(s): Wu, Julie
• Application Number:
  US14/109,606
• Publication Number:
  US 20140212925A1
• Time in Patent Office: 1,001 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/6879 the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0031 Rectum, anus
• CPC Class Codes: A61K 9/0034 Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
• CPC Class Codes: A61K 9/0043 Nose
• CPC Class Codes: A61K 9/0053 Mouth and digestive tract, i.e. intraoral and peroral administration rectal administration A61K9/0031
• CPC Class Codes: A61K 9/006 Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
• CPC Class Codes: A61K 9/007 Pulmonary tract; Aromatherapy
• CPC Class Codes: A61K 9/0085 Brain, e.g. brain implants; Spinal cord
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/14 Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 1/18 for pancreatic disorders, e.g. pancreatic enzymes
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/02 Nasal agents, e.g. decongestants
• CPC Class Codes: A61P 11/04 : for throat disorders
• CPC Class Codes: A61P 11/06 : Antiasthmatics
• CPC Class Codes: A61P 11/16 : Central respiratory analeptics
• CPC Class Codes: A61P 13/02 : of urine or of the urinary tract, e.g. urine acidifiers
• CPC Class Codes: A61P 13/08 : of the prostate
• CPC Class Codes: A61P 13/12 : of the kidneys
• CPC Class Codes: A61P 15/02 : for disorders of the vagina
• CPC Class Codes: A61P 15/08 : for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• CPC Class Codes: A61P 15/10 : for impotence
• CPC Class Codes: A61P 17/00 : Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 : for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/04 : Antipruritics
• CPC Class Codes: A61P 17/06 : Antipsoriatics
• CPC Class Codes: A61P 17/08 : Antiseborrheics
• CPC Class Codes: A61P 17/14 : for baldness or alopecia
• CPC Class Codes: A61P 19/00 : Drugs for skeletal disorders
• CPC Class Codes: A61P 19/02 : for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/06 : Antigout agents, e.g. antihyperuricemic or uricosuric agents
• CPC Class Codes: A61P 19/10 : for osteoporosis
• CPC Class Codes: A61P 21/00 : Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 21/02 : Muscle relaxants, e.g. for tetanus or cramps
• CPC Class Codes: A61P 21/04 : for myasthenia gravis
• CPC Class Codes: A61P 25/00 : Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/04 : Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 25/06 : Antimigraine agents
• CPC Class Codes: A61P 25/14 : for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/16 : Anti-Parkinson drugs
• CPC Class Codes: A61P 25/18 : Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/22 : Anxiolytics
• CPC Class Codes: A61P 25/24 : Antidepressants
• CPC Class Codes: A61P 25/28 : for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 25/30 : for treating abuse or dependence
• CPC Class Codes: A61P 25/32 : Alcohol-abuse
• CPC Class Codes: A61P 27/02 : Ophthalmic agents
• CPC Class Codes: A61P 27/14 : Decongestants or antiallergics
• CPC Class Codes: A61P 29/00 : Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/00 : Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/02 : Nutrients, e.g. vitamins, minerals
• CPC Class Codes: A61P 3/06 : Antihyperlipidemics
• CPC Class Codes: A61P 3/08 : for glucose homeostasis pancreatic hormones A61P5/48
• CPC Class Codes: A61P 3/10 : for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 3/14 : for calcium homeostasis vitamin D A61P3/02; parathyroid hormones A61P5/18; calcitonin A61P5/22; osteoporosis A61P19/10; bone metastasis A61P35/04
• CPC Class Codes: A61P 31/00 : Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 : Antibacterial agents
• CPC Class Codes: A61P 31/06 : for tuberculosis
• CPC Class Codes: A61P 31/08 : for leprosy
• CPC Class Codes: A61P 31/10 : Antimycotics
• CPC Class Codes: A61P 31/12 : Antivirals
• CPC Class Codes: A61P 31/14 : for RNA viruses
• CPC Class Codes: A61P 31/16 : for influenza or rhinoviruses
• CPC Class Codes: A61P 31/18 : for HIV
• CPC Class Codes: A61P 31/20 : for DNA viruses
• CPC Class Codes: A61P 33/00 : Antiparasitic agents
• CPC Class Codes: A61P 33/02 : Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
• CPC Class Codes: A61P 33/06 : Antimalarials
• CPC Class Codes: A61P 33/08 : for Pneumocystis carinii
• CPC Class Codes: A61P 35/00 : Antineoplastic agents
• CPC Class Codes: A61P 35/02 : specific for leukemia
• CPC Class Codes: A61P 37/00 : Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 : Immunomodulators
• CPC Class Codes: A61P 37/04 : Immunostimulants
• CPC Class Codes: A61P 37/06 : Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 37/08 : Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 39/02 : Antidotes
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/00 : Drugs for disorders of the endocrine system
• CPC Class Codes: A61P 5/14 : of the thyroid hormones, e.g. T3, T4
• CPC Class Codes: A61P 5/16 : for decreasing, blocking or antagonising the activity of the thyroid hormones
• CPC Class Codes: A61P 5/18 : of the parathyroid hormones
• CPC Class Codes: A61P 5/48 : of the pancreatic hormones
• CPC Class Codes: A61P 5/50 : for increasing or potentiating the activity of insulin
• CPC Class Codes: A61P 7/02 : Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 7/04 : Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• CPC Class Codes: A61P 7/06 : Antianaemics
• CPC Class Codes: A61P 7/08 : Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock artificial tears A61P27/04
• CPC Class Codes: A61P 7/10 : Antioedematous agents; Diuretics
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/04 : Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• CPC Class Codes: A61P 9/06 : Antiarrhythmics
• CPC Class Codes: A61P 9/08 : Vasodilators for multiple indications
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/12 : Antihypertensives
• CPC Class Codes: A61P 9/14 : Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
• CPC Class Codes: C07K 14/545 : IL-1
• CPC Class Codes: C07K 16/245 : IL-1
• CPC Class Codes: C07K 16/468 : Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
• CPC Class Codes: C07K 2317/24 : containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/31 : multispecific
• CPC Class Codes: C07K 2317/33 : Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
• CPC Class Codes: C07K 2317/56 : variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C07K 2317/565 : Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/64 : comprising a combination of variable region and constant region components
• CPC Class Codes: C07K 2317/76 : Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/92 : Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• CPC Class Codes: G01N 2333/545 : IL-1
• CPC Class Codes: G01N 2800/00 : Detection or diagnosis of diseases
• CPC Class Codes: G01N 33/6869 : Interleukin
• CPC Class Codes: Y02A 50/30 : Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions.

Claims

1. An isolated nucleic acid encoding the amino acid sequence of an IL-1β

binding protein comprising an antigen binding domain, said binding protein capable of binding human IL-1β

, said antigen binding domain comprising six CDRs;

CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, as defined below;

2. A vector comprising an isolated nucleic acid according to claim 1.

3. A host cell comprising a vector according to claim 2.

4. A method of producing an IL-1β

binding protein, comprising culturing a host cell described in claim 3 in culture medium under conditions sufficient to produce the IL-1β

binding protein.

5. The isolated nucleic acid according to claim 1, comprising CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3

wherein the CDR-H1 is an amino acid selected from the group consisting of

residues 31-35 of SEQ ID NO:

60;

residues 31-35 of SEQ ID NO;

61;

residues 31-35 of SEQ ID NO;

114; and

residues 31-35 of SEQ ID NO;

117;

wherein the CDR-H2 is an amino acid selected from the group consisting of

residues 50-66 of SEQ ID NO;

60;

residues 50-66 of SEQ ID NO;

71;

residues 50-66 of SEQ ID NO;

105;

residues 50-66 of SEQ ID NO;

113;

residues 50-66 of SEQ ID NO;

123;

residues 50-66 of SEQ ID NO;

131; and

residues 50-66 of SEQ ID NO;

133;

wherein the CDR-H3 is an amino acid selected from the group consisting of

residues 99-108 of SEQ ID NO;

60 (CDR-H3);

residues 99-108 of SEQ ID NO;

61 (CDR-H3);

residues 99-108 of SEQ ID NO;

64 (CDR-H3);

residues 99-108 of SEQ ID NO;

78 (CDR-H3);

residues 99-108 of SEQ ID NO;

87 (CDR-H3);

residues 99-108 of SEQ ID NO;

92 (CDR-H3);

residues 99-108 of SEQ ID NO;

104 (CDR-H3); and

residues 99-108 of SEQ ID NO;

140 (CDR-H3);

wherein the CDR-L1 is an amino acid selected from the group consisting of

residues 24-34 of SEQ ID NO;

59 (CDR-L1);

residues 24-34 of SEQ ID NO;

149 (CDR-L1);

residues 24-34 of SEQ ID NO;

150 (CDR-L1);

residues 24-34 of SEQ ID NO;

151 (CDR-L1);

residues 24-34 of SEQ ID NO;

153 (CDR-L1);

residues 24-34 of SEQ ID NO;

156 (CDR-L1);

residues 24-34 of SEQ ID NO;

159 (CDR-L1);

residues 24-34 of SEQ ID NO;

164 (CDR-L1);

residues 24-34 of SEQ ID NO;

167 (CDR-L1);

residues 24-34 of SEQ ID NO;

174 (CDR-L1);

residues 24-34 of SEQ ID NO;

179 (CDR-L1); and

residues 24-34 of SEQ ID NO;

188 (CDR-L1);

wherein the CDR-L2 is an amino acid selected from the group consisting of

residues 50-56 of SEQ ID NO;

59 (CDR-L2);

residues 50-56 of SEQ ID NO;

149 (CDR-L2);

residues 50-56 of SEQ ID NO;

151(CDR-L2);

residues 50-56 of SEQ ID NO;

156 (CDR-L2);

residues 50-56 of SEQ ID NO;

167 (CDR-L2);

residues 50-56 of SEQ ID NO;

169 (CDR-L2);

residues 50-56 of SEQ ID NO;

171 (CDR-L2);

residues 50-56 of SEQ ID NO;

175 (CDR-L2);

residues 50-56 of SEQ ID NO;

176 (CDR-L2);

residues 50-56 of SEQ ID NO;

178 (CDR-L2);

residues 50-56 of SEQ ID NO;

180 (CDR-L2);

residues 50-56 of SEQ ID NO;

181 (CDR-L2);

residues 50-56 of SEQ ID NO;

185 (CDR-L2); and

residues 50-56 of SEQ ID NO;

187 (CDR-L2);

or

wherein the CDR-L3 is an amino acid selected from the group consisting of

residues 89-97 of SEQ ID NO;

59 (CDR-L3);

residues 89-97 of SEQ ID NO;

149 (CDR-L3);

residues 89-97 of SEQ ID NO;

150 (CDR-L3);

residues 89-97 of SEQ ID NO;

151 (CDR-L3);

residues 89-97 of SEQ ID NO;

155 (CDR-L3);

residues 89-97 of SEQ ID NO;

160 (CDR-L3);

residues 89-97 of SEQ ID NO;

167 (CDR-L3);

residues 89-97 of SEQ ID NO;

176 (CDR-L3);

residues 89-97 of SEQ ID NO;

181 (CDR-L3);

residues 89-97 of SEQ ID NO;

182 (CDR-L3);

residues 89-97 of SEQ ID NO;

183 (CDR-L3); and

residues 89-97 of SEQ ID NO;

188 (CDR-L3).

6. The isolated nucleic acid according to claim 1, wherein at least three CDRs are from a set of CDRs selected from the group of CDR sets consisting of:

7. The isolated nucleic acid according to claim 6, comprising CDRs from two CDR sets, wherein said two CDR sets comprise a VH CDR Set selected from the group consisting of CDR Sets 1-23, and a VL CDR Set selected from the group consisting of CDR Sets 24-56.

8. The isolated nucleic acid according to claim 7, further comprising a human acceptor framework.

9. The isolated nucleic acid according to claim 8, wherein said human acceptor framework comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:

7-10, 13-16, 25, 240-316, and 317-381.

10. The isolated nucleic acid according to claim 8, wherein said human acceptor framework comprises at least one framework region amino acid substitution, wherein the amino acid sequence of the framework is at least 65% identical to the sequence of said human acceptor framework and comprises at least 70 amino acid residues identical to said human acceptor framework.

11. The isolated nucleic acid according to claim 8, wherein said human acceptor framework comprises at least one framework region amino acid substitution at a key residue, said key residue selected from the group consisting of a residue adjacent to a CDR;

a glycosylation site residue;

a rare residue;

a residue capable of interacting with human IL-1β

;

a residue capable of interacting with a CDR;

a canonical residue;

a contact residue between heavy chain variable region and light chain variable region;

a residue within a Vernier zone; and

a residue in a region that overlaps between a Chothia-defined variable heavy chain CDR1 and a Kabat-defined first heavy chain framework.

12. The isolated nucleic acid according to claim 11, wherein the key residue by Kabat numbering is selected from the group consisting of:

2H, 4H, 24H, 26H, 27H, 29H, 34H, 35H, 37H, 39H, 44H, 45H, 47H, 48H, 49H, 50H, 51H, 58H, 59H, 60H, 63H, 67H, 69H, 71H, 73H, 76H, 78H, 91H, 93H, 94H, 2L, 4L, 25L, 29L, 27bL, 33L, 34L, 36L, 38L, 43L, 44L, 46L, 47L, 48L, 49L, 55L, 58L, 62L, 64L, 71L, 87L, 89L, 90L, 91L, 94L, and 95L.

13. The isolated nucleic acid according to claim 8, wherein the binding protein comprises a consensus human variable domain.

14. The isolated nucleic acid according to claim 7, wherein said binding protein comprises at least one variable domain having an amino acid sequence selected from the group consisting of SEQ ID NOs:

59-122 and 124-211.

15. The isolated nucleic acid according to claim 14, wherein said binding protein comprises two variable domains.

16. The isolated nucleic acid according to claim 15, wherein said two variable domains comprise amino acid sequences selected from the group consisting of:

17. The isolated nucleic acid according to claim 7, wherein said two CDR sets comprise CDR Set 5 and CDR Set 56.

18. The isolated nucleic acid according to claim 14, wherein said at least one variable domain comprises the amino acid sequences of SEQ ID NO:

204 and SEQ ID NO;

205.